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Abstract
Service users within the NHS are increasingly being asked to participate in clinical research. In
Liverpool Women's NHS Foundation Trust, approximately 35% of women take part in research
during their pregnancy. For many studies the consent process is simple; information is provided and
signed consent is given. There is a difficulty, however, with obtaining informed consent from
women in pregnancy who become eligible only when they develop unforeseen complications,
especially when they occur acutely. The problem is compounded with women in labour who may
be frightened, vulnerable, in pain, under the effect of opiate analgesia, or all of the above. If research
to improve the care of these women is to continue, then special consent procedures are needed.
These procedures must ensure that the woman's autonomy is protected whilst recognising that
women under these circumstances vary enormously, both in their desire for information and their
ability to comprehend it. This paper will discuss the obtaining of consent in this situation, and
describe an information and consent pathway for intrapartum research which has been developed
in collaboration with consumer groups as a way in which these issues can be tackled.
Introduction
Ethical issues concerning research on human subjects
have been covered extensively and there are a number of
guidelines published to provide authoritative advice for
the research community [1-5]. Such guidance usually
states that informed consent must be gained from the trial
participants before they can be recruited to the trial. Ide-
ally, several days should be allowed for individuals to
consider the research, and their possible participation in
it, giving them a chance to discuss it with their families,
friends and family doctor [4]. The patient's consent is then
initially confirmed with a signature, although it should be
made clear that the agreement is not binding.
It is widely acknowledged that there are vulnerable groups
from whom gaining consent for clinical research presents
ethical difficulties. Such groups include children, young
people and adults who 'lack capacity', for example those
with mental illness or learning difficulties. Specialised
guidance concerning gaining consent from these specific
groups is available [3,7]. One vulnerable group, however,
which appears to have been forgotten, is labouring
women. Guidelines addressing the recruitment of women
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into intrapartum clinical trials are not yet readily available
from the professional organisations, although 3 con-
sumer groups [Association for Improvements in the Mid-
wifery Services (AIMS), National Childbirth Trust (NCT)
and the Maternity Alliance] have gone some way in
addressing this need with the publication of their 'Charter
for Ethical research in Maternity Care' in 1997 [6].
The Release trial is an example of an ongoing intrapartum
randomised controlled trial for which a trial-specific
information and consent pathway was developed in col-
laboration with consumer groups. This paper describes
this pathway and discusses its possible adaptation for
future intrapartum research. This is particularly important
as there are fears that in attempting to safeguard the well-
being of trial participants, consent procedures could pre-
vent intrapartum research. Furthermore, studies suggest
that women value the opportunity to take part in research
[8,9], and from a medical perspective it is clear that good
quality research is crucial if the quality of intrapartum care
is to improve.
The Release trial
The Release trial is an intrapartum randomised-controlled
trial of umbilical oxytocin injection for the treatment of
retained placenta. Retained placenta occurs after 2% of
deliveries and is diagnosed when the placenta fails to
deliver 30 minutes after childbirth. Due to its acute clini-
cal context it has thrown up a number of ethical issues
concerning informed consent. The consent pathway for
the trial was developed in consultation with local and
national consumer groups, local experts in the field of
consent issues and the London Multi-centre Research and
Ethics Committee (MREC). The issues faced during this
process are detailed below, with examples of how the
Release trial addressed them and points for consideration
by other researchers.
Antenatal information
The provision of sufficient accurate information is an
essential part of seeking informed consent. Indeed, when
seeking consent the quality and clarity of the information
given should be the paramount consideration [3]. For
intrapartum trials it is not possible to fulfil all of the crite-
ria above, especially that of time. Hence, there has been a
move to provide information to all pregnant women ante-
natally, despite the fact that only a small number will be
eligible to participate in a study. However, there is a con-
flict between promoting 'normality' in pregnancy and
labour, and routinely presenting women with research
information. For many women the risk of experiencing
these adverse events is small and to present women with
a detailed discussion of each complication's symptoms
and management risks, unnecessarily detracts from
labour as being a normal physiological process.
To date there have been no studies specifically designed to
evaluate women's antenatal information requirements
concerning obstetric complications and associated
research. However, a study by Jackson and colleagues in
Canada studied women's desire for information about
risks associated with epidural analgesia [10]. The research-
ers used a questionnaire covering demographic data, epi-
dural and consent information. Fifty six women who had
requested an epidural were asked to give a score between
0 and 10 for the question 'risks should be discussed prior
to labour'. The average score to this question was 8/10 (0
= least, 10 = most). The authors concluded that labouring
women want to hear about all potential epidural compli-
cations, and for risks to be explained to them before
labour. Although this study addressed information
regarding risks associated with a treatment, specifically
epidural analgesia, it may suggest that some women wish
to be informed of potential risks associated with intrapar-
tum research before they go into labour.
A prospective study of women's views by Lavender and
colleagues explored aspects of childbirth that women per-
ceived as being important and as contributing to a posi-
tive birth experience [9]. Women considered information
to be an important factor contributing to a positive labour
experience, with 154 (37%) feeling unprepared for labour
because of either a lack of information or their own unre-
alistic expectations. Some women stated that they wished
they had had more information antenatally. Those
women who felt prepared, and who felt they had acquired
adequate and accurate information were less likely to view
their labour negatively. The nature of the information
women would regard as adequate, or that they would like
to receive antenatally requires further exploration.
For the Release trial antenatal information is provided
through a variety of means. First, brief information is pro-
vided to women at the 'booking' visit at 9–14 weeks, in
the form of an A4 information sheet in their case notes.
This information provides an introduction to the study –
what it is called, why it is being conducted, a brief over-
view of the technique being evaluated, and who to contact
for further information. Additional information in the
form of a 4-page tabloid-style brochure has also been dis-
tributed in antenatal clinics and is available on labour
wards in the UK trial sites (figure 1). The purpose of this
is to provide further details of who the study is organised
by and how it is funded. It also provides further details of
the technique being evaluated, advice on how to take part,
contact details and pictures of the research team so as to
develop familiarity. These sources of information are
backed up with posters in the antenatal clinics and public-
ity in the local press.Trials 2006, 7:13 http://www.trialsjournal.com/content/7/1/13
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All the above publicity is provided to raise awareness of
the trial antenatally and give women the option of obtain-
ing more information if they wish.
Web-based information
For each individual the requirement for information is
different depending on their personality, time pressures,
and interest. Some women will wish to know in advance
every risk associated with pregnancy and the research
being conducted to address those adverse events, while
others may not wish to know about such risks prior to
them arising.
A good medium to use for addressing differing informa-
tion requirements is the internet. As a source of informa-
tion, it allows a person to obtain as little or as much
information as they wish, and to retrieve that in which
they are interested.
In all of the Release study documentation available to
women, reference is made to the study website to which
women may turn to address their different information
needs (figure 2). The website provides information of a
varying nature; non-clinical and clinical, plus latest news
items and downloadable resources including presenta-
tions and trial documents. It therefore provides a good
source of information addressing questions of a various
nature and level. However, there are limitations associ-
ated with the dissemination of research information via
the internet, for example not all potential participants will
have access to computers and, for smaller studies, the
expense of setting up and maintaining a website may be
prohibitive.
Information at the time of recruitment
Finally, there is the controversial issue of seeking consent
while a woman is in labour. It may be argued that some
women are unable to give their full attention to the details
of a research study and to think carefully about the impli-
cations of becoming involved in the research while they
are in labour. During this time women may be experienc-
ing painful contractions, drowsy through the effects of
opioids and anxious about the possibility of complica-
tions. In addition, many women may feel vulnerable.
They may therefore be afraid of not complying with their
carer's suggestions and may feel pressurised into giving
their consent to participate in clinical research. As such, it
is possible that a woman's competence to give informed
consent during labour may be compromised [11].
In some trials of emergency treatments outside labour,
researchers have sought retrospective consent [12,13].
Whilst this may be suitable for trials in which the time
period between diagnosis and need for randomisation is
very short or the patient is clearly incapacitated, being in
labour is not in itself an indication for doing this. Jackson
and colleagues found that women in labour were as able
to give informed consent as are other members of the
patient population [10]. The investigators surveyed 60
women who were actively in labour without epidural
analgesia, to assess women's ability to understand epi-
dural risks during this time. They found that the women
wanted to know about labour epidural analgesia and have
all risks disclosed. The authors concluded that no antici-
pated variable (i.e. labour pain, anxiety, opioid pre-medi-
cation, duration of labour pain, desire for an epidural,
previous epidural experience or level of education or age)
correlated with a woman's ability to understand epidural
risks, and that all of the women had at least a moderate
understanding of the risks during active labour. A further
study investigated the ability of women in labour to recall
the risks of epidural, previously explained to them in
labour [14]. This study also questions the assumption that
women in labour lack the capacity to give informed con-
Front cover of the Release study newsletter Figure 1
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sent. The recall of risks by women in labour was found to
be similar to that of other patient groups, and did not
appear to be affected by parity or the reported level of
pain.
So if women can comprehend the research despite the
stress of labour, do they feel pressurised to participate due
to their vulnerable state? A study by Dorantes and col-
leagues, looking at the factors that influence women's
decisions to participate in obstetric anaesthesia research,
suggested that the environment, in which consent for
obstetric studies was sought, was not coercive [15]. In this
study, only one woman out of 166 consenters reported
feeling pressurised to consent.
For the Release trial, these issues were addressed by con-
sultation with consumer groups who provided valuable
input from women's perspectives, addressing questions
raised by the ethics committees during the process of pro-
tocol development. The result was a consent pathway (fig-
ure 3) drawn up by the University of Liverpool School of
Reproductive and Developmental Medicine in collabora-
tion with the North West Obstetrics and Gynaecology
Clinical Trials Network (NWCTN), and representatives
from local consumer groups.
When the diagnosis of retained placenta is made, 30 min-
utes following delivery of the baby, the trial may be dis-
cussed by the researcher in further detail with her
attending midwife or doctor to ascertain whether it is
appropriate to approach her, considering her emotional
and physical state. Whilst this would be considered good
research practice anyway, this role should be made
explicit, with the primary carer acting as gatekeeper on
behalf of the labouring woman, preventing unwanted dis-
turbance and acting as advocate for her. If appropriate, the
woman will then be provided with a more detailed infor-
mation sheet, which is also available in Somali, Arabic,
Release study website homepage http://www.releasestudy.org Figure 2
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and Luganda, and which contains a flow diagram to facil-
itate understanding. This information builds upon that
the woman received from the various sources antenatally.
At this point, the doctor or midwife seeking consent, who
will be fully trained in consent procedures, would confirm
some level of understanding on the woman's part, by
encouraging her to reiterate important points of the study.
Only following this will formal written consent be sought.
Discussion
Evidence suggests that despite concerns of vulnerability,
pain and opiate analgesia, women do have the capacity to
give informed consent to take part in intrapartum studies.
Furthermore, women are often willing to participate in
research, although it is acknowledged that there are many
contributing factors to their decision making processes,
depending upon their individual circumstances and
beliefs [16]. This capacity, willingness and complexity
warrants the need for guidance in the process of gaining
consent in intrapartum trials to ensure researchers seek
consent according to good ethical principles. Current
guidance developed by professionals in conjunction with
individual consumers appears to display a lack of under-
standing of what consumers want, and struggles to strike
a balance between providing adequate information with-
out causing information overload and unnecessary anxi-
ety. In this paper, we have described a pathway developed
as one way to tackle these issues.
The information and consent pathway proposed here
seeks to ensure that women have the opportunity to
become fully informed. However, there is a choice issue
which requires consideration when it comes to adhering
to the fully informed consent process prescribed by ethics
committees. When providing perinatal research informa-
tion it is important to note that some women may prefer
not to consider all of the information, and should perhaps
be given the option to 'opt-out' of the fully informed con-
sent process. Anecdotal evidence suggests that some
women would prefer not to have to choose whether or not
to participate in research, and would feel relieved if the
onus was removed from them, indeed some women
expressed their belief that research need not be mentioned
and should be incorporated into routine care [16].
Up to now, the lack of coherent guidance has made it
problematic for the research community to gain ethical
approval for recruiting women into perinatal clinical tri-
als. Currently, the onus is on individual researchers to
argue their case to ethics committees on gaining ethical
approval for perinatal studies based on individual
research protocols. This is leading to inconsistent and
often conflicting advice from various ethics and research
bodies, concerning best practice in seeking consent from
women participating in perinatal clinical trials. In turn,
this may lead to confusion and deter research into perina-
tal adverse events.
Ethics and research bodies request that women be fully
informed before consent is sought to participate in intra-
partum trials. However, given the issues addressed in this
paper, it is difficult to assess if a woman is indeed fully
informed before seeking consent. A questionnaire survey
of women who participated in the ORACLE trial (a trial of
antibiotics in preterm labour) suggested that no matter
how well we try to optimise the provision of information,
it may not always be possible to demonstrate full under-
standing of trial purpose by participants [17]. Therefore
emphasis should be placed on presenting information as
fully as possible and having consumers involved in the
writing and design process in an attempt to enhance
understanding.
It is important therefore to consider to what extent we
should negotiate. For example, if women do not receive
adequate information antenatally either because of lack of
access, or by choice (opting out of the fully informed con-
sent process), should they automatically be excluded from
Consent pathway for intrapartum research Figure 3
Consent pathway for intrapartum research.Trials 2006, 7:13 http://www.trialsjournal.com/content/7/1/13
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research without giving them the choice to participate? Is
this not unethical in itself?
These issues add to the concerns of the research commu-
nity in general, regarding the increasingly complex proce-
dures for gaining ethical approval to conduct clinical
research. The process of gaining ethical approval in the UK
has been described as 'bureaucratic' [18,19]. The concern
is that important trials will be unnecessarily delayed, will
incur additional costs without any increased protection
for trial subjects and that UK partners may become unwel-
come in international trials [18].
We are not proposing a standardised approach to seeking
informed consent, but a framework with optional ele-
ments that can be adjusted to take into account the indi-
viduality of both the study and the women who are
participating in it. Evidence suggests that women consider
an individualised research approach towards them as
important and that they want their individual situations
to be acknowledged. If this is done then it is likely to
encourage research participation [16]. Exactly how this
can be achieved for a particular study is an area for further
exploration by the researchers concerned.
From the experience of the Release trial it was important
to involve consumer groups at an early stage of protocol
development to consider how it was most appropriate
and acceptable to women, to seek consent during third
stage labour. It has also been important to consider the
resource implications of developing, maintaining and
staffing the elements of the agreed pathway throughout
the duration of the trial. It is also apparent that compli-
ance to the information and consent pathway may vary
from site to site, and this needs to be monitored through-
out the trial. Formal assessment of the Release consent
process is ongoing within its principle site at Liverpool
Women's NHS Foundation Trust. The authors will report
their findings in due course as to whether the information
and consent pathway they propose here has achieved the
desired outcome in terms of the provision of appropriate
information to help women make informed decisions
about their participation in intrapartum research.
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